ProKidney (PROK) Stock Price, News & Analysis

Company Overview

ProKidney, Inc. (NASDAQ: PROK) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment of kidney diseases. Leveraging its proprietary XRx™ platform, ProKidney focuses on small-molecule compounds designed to enhance cellular resilience and slow the progression of acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting underlying mechanisms of renal dysfunction, the company aims to address significant unmet medical needs and improve patient outcomes across a broad spectrum of nephrological conditions.

The company’s lead programs include first-in-class candidate PKX-001, which is being evaluated for its ability to protect renal cells from ischemic damage and oxidative stress. ProKidney’s pipeline also features a series of follow-on compounds optimized for oral administration and long-term safety in CKD patients. In addition to therapeutic development, the firm is exploring partnerships with contract research organizations and academic centers to validate its platform across diverse preclinical models, setting the stage for future clinical trials.

Founded in 2020 as a spin-off from academic research on renal cell biology, ProKidney is headquartered in Boston, Massachusetts, with R&D operations in Cambridge. The company has established collaborations in North America and Europe to support regulatory strategy, manufacturing scale-up, and clinical trial execution. These strategic relationships aim to expedite the progression of ProKidney’s candidates through Phase 1 and Phase 2 studies, ultimately positioning the company for pivotal trials in key global markets.

ProKidney’s leadership team brings together seasoned professionals from the biotechnology and pharmaceutical industries, including experts in nephrology, drug development, and regulatory affairs. Under the guidance of its executive management and scientific advisory board, the company continues to refine its pipeline, secure intellectual property, and prepare for future commercialization efforts that could transform the standard of care for patients living with kidney disease.

Key Stats

• Today's Range: $3.09 to $3.56
• 50-Day Range: $0.57 to $5.18
• 52-Week Range: $0.46 to $7.13
• Volume: 6.55 million shs
• Average Volume: 3.61 million shs
• Market Capitalization: $922.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.25
• Consensus Rating: Hold

ProKidney Stock Analysis - MarketRank™

ProKidney scored higher than 71% of companies evaluated by MarketBeat, and ranked 340th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

ProKidney has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

ProKidney has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ProKidney are expected to grow in the coming year, from ($0.57) to ($0.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ProKidney is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ProKidney is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.90% of the float of ProKidney has been sold short.

Short Interest Ratio / Days to Cover

ProKidney has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProKidney has recently decreased by 16.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ProKidney does not currently pay a dividend.

Dividend Growth

ProKidney does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.90% of the float of ProKidney has been sold short.

Short Interest Ratio / Days to Cover

ProKidney has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProKidney has recently decreased by 16.49%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.75

News Sentiment

ProKidney has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for ProKidney this week, compared to 2 articles on an average week.

Search Interest

33 people have searched for PROK on MarketBeat in the last 30 days. This is an increase of 3,200% compared to the previous 30 days.

MarketBeat Follows

11 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Balanced

Insider Buying vs. Insider Selling

In the past three months, ProKidney insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $275,049.00 in company stock and sold $312,510.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.

Percentage Held by Insiders

41.49% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PROK Stock Analysis - Frequently Asked Questions

How have PROK shares performed this year?

ProKidney's stock was trading at $1.69 at the start of the year. Since then, PROK shares have increased by 86.4% and is now trading at $3.15.

How were ProKidney's earnings last quarter?

ProKidney Corp. (NASDAQ:PROK) announced its earnings results on Monday, May, 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. The business had revenue of $0.23 million for the quarter.

How do I buy shares of ProKidney?

Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ProKidney own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProKidney investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PROK
• CIK: 1850270
• Web: www.prokidney.com
• Phone: 336-999-7028
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ProKidney: $6.25
• High Price Target: $9.00
• Low Price Target: $1.00
• Potential Upside/Downside: +98.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.19 million
• Net Margins: N/A
• Pretax Margin: -54,267.64%
• Return on Equity: N/A
• Return on Assets: -15.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.96
• Quick Ratio: 10.96

Sales & Book Value

• Annual Sales: $80 thousand
• Price / Sales: 11,525.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.41) per share
• Price / Book: -0.92

Miscellaneous

• Outstanding Shares: 292,700,000
• Free Float: 171,258,000
• Market Cap: $922.01 million
• Optionable: Optionable
• Beta: 1.26